Accuray receives fda clearance for vitalhold™ on the radixact® system; breast cancer treatment option will also be available in the eu market

The radixact system, with the addition of the vitalhold functionality, provides clinicians with unmatched choice of radiation treatment delivery options in one device treatment delivery versatility offers opportunities for personalization and makes exceptional quality care possible for more breast cancer patients madison, wis. , aug. 9, 2023 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that the company has received 510(k) clearance from the u.s. food and drug administration (fda) for its vitalhold™* breast package on the radixact ® system.
ARAY Ratings Summary
ARAY Quant Ranking